ACP-204 is under clinical development by Acadia Pharmaceuticals and currently in Phase I for Psychosis. According to GlobalData, Phase I drugs for Psychosis have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACP-204’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACP-204 is under development for the treatment of Alzheimer’s disease psychosis.
Acadia Pharmaceuticals overview
Acadia Pharmaceuticals (Acadia) discovers, develops, and commercializes small molecule drugs for the treatment of central nervous system (CNS) disorders. The company’s marketed product Nuplazid (pimavanserin) is an FDA-approved drug for the treatment of Parkinson’s disease psychosis. It’s pipeline includes pimavanserin for the treatment of various indications which include Schizophrenia, Major Depressive Disorder (MDD), dementia-related psychosis (DRP), and trofinetide for the treatment of Rett Syndrome. The company markets its product in the US. It has operational presence in Denmark, Switzerland, and the UK. Acadia is headquartered in San Diego, California, the US.
For a complete picture of ACP-204’s drug-specific PTSR and LoA scores, buy the report here.